Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
J Sadoff, ML Gars, G Shukarev, D Heerwegh, C Truyers… - MedRxiv, 2020 - medrxiv.org
ABSTRACT BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be …
Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
J Sadoff, M Le Gars, G Shukarev, D Heerwegh… - (No Title), 2020 - cir.nii.ac.jp
抄録< jats: title> ABSTRACT</jats: title>< jats: sec>< jats: title> BACKGROUND</jats: title><
jats: p> The ongoing coronavirus disease (COVID)-19 pandemic caused by severe acute …
jats: p> The ongoing coronavirus disease (COVID)-19 pandemic caused by severe acute …
[PDF][PDF] Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results 1 of a phase 1/2a, double-blind, randomized, placebo-controlled …
J Sadoff, M Le Gars, G Shukarev, D Heerwegh… - optumhealtheducation.com
1 Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results
1 of a phase 1/2a, double-blind, rand Page 1 1 Safety and immunogenicity of the …
1 of a phase 1/2a, double-blind, rand Page 1 1 Safety and immunogenicity of the …
[PDF][PDF] Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results 1 of a phase 1/2a, double-blind, randomized, placebo-controlled …
J Sadoff, M Le Gars, G Shukarev, D Heerwegh… - scholar.archive.org
1 Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results
1 of a phase 1/2a, double-blind, rand Page 1 1 Safety and immunogenicity of the …
1 of a phase 1/2a, double-blind, rand Page 1 1 Safety and immunogenicity of the …
[HTML][HTML] Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled …
J Sadoff, M Le Gars, G Shukarev, D Heerwegh… - medRxiv, 2020 - medrxiv.org
ABSTRACT BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be …
Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
J Sadoff, M Le Gars, G Shukarev, D Heerwegh… - 2020 - pesquisa.bvsalud.org
BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …
[HTML][HTML] Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled …
J Sadoff, ML Gars, G Shukarev, D Heerwegh, C Truyers… - 2020 - europepmc.org
BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …
Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
J Sadoff, M Le Gars, G Shukarev, D Heerwegh… - 2020 - pesquisa.bvsalud.org
BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …